Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2007. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,200,000 ordinary shares of 25 pence each.
- Purchase Price: 1,305.4643 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.15% of total voting rights).
- Shares in Issue: 5,507,768,059 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,200,000 shares. Consequently, the total number of shares in issue was adjusted to 5,507,768,059. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total share count of 5,507,768,059 for calculating ownership percentages under Disclosure Transparency Rules.
- Confirm the Treasury share holding of 504,194,158 shares and its impact on the 9.15% voting rights representation.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.